Robeco Institutional Asset Management B.V. Increases Stock Position in IQVIA Holdings Inc. (NYSE:IQV)

Robeco Institutional Asset Management B.V. grew its stake in IQVIA Holdings Inc. (NYSE:IQV) by 0.6% during the third quarter, according to its most recent 13F filing with the SEC. The firm owned 118,394 shares of the medical research company’s stock after acquiring an additional 674 shares during the period. Robeco Institutional Asset Management B.V. owned about 0.06% of IQVIA worth $28,056,000 as of its most recent filing with the SEC.

Several other large investors have also recently made changes to their positions in the stock. PGGM Investments lifted its stake in IQVIA by 55.8% during the second quarter. PGGM Investments now owns 12,073 shares of the medical research company’s stock worth $2,553,000 after purchasing an additional 4,326 shares in the last quarter. SG Americas Securities LLC lifted its stake in IQVIA by 80.1% during the 1st quarter. SG Americas Securities LLC now owns 45,787 shares of the medical research company’s stock worth $11,579,000 after acquiring an additional 20,369 shares in the last quarter. Quadrature Capital Ltd purchased a new position in IQVIA during the 1st quarter valued at about $3,365,000. Raymond James & Associates increased its stake in IQVIA by 0.7% during the second quarter. Raymond James & Associates now owns 800,374 shares of the medical research company’s stock worth $169,231,000 after purchasing an additional 5,417 shares during the period. Finally, UniSuper Management Pty Ltd lifted its position in shares of IQVIA by 253.0% during the first quarter. UniSuper Management Pty Ltd now owns 6,029 shares of the medical research company’s stock worth $1,525,000 after purchasing an additional 4,321 shares in the last quarter. 89.62% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other news, insider Eric Sherbet sold 1,300 shares of the firm’s stock in a transaction that occurred on Tuesday, August 27th. The shares were sold at an average price of $246.33, for a total transaction of $320,229.00. Following the transaction, the insider now directly owns 19,536 shares in the company, valued at approximately $4,812,302.88. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. 1.60% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

A number of brokerages recently weighed in on IQV. Truist Financial dropped their price objective on shares of IQVIA from $286.00 to $265.00 and set a “buy” rating for the company in a report on Monday. Deutsche Bank Aktiengesellschaft cut their price objective on IQVIA from $270.00 to $265.00 and set a “buy” rating on the stock in a research report on Friday, November 1st. Robert W. Baird decreased their target price on IQVIA from $256.00 to $223.00 and set a “neutral” rating for the company in a report on Friday, November 1st. Redburn Atlantic started coverage on IQVIA in a report on Monday, October 14th. They set a “buy” rating and a $276.00 price target on the stock. Finally, Royal Bank of Canada reiterated an “outperform” rating and issued a $270.00 price objective on shares of IQVIA in a research note on Friday, November 1st. Four analysts have rated the stock with a hold rating, fifteen have issued a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, IQVIA currently has an average rating of “Moderate Buy” and an average target price of $259.13.

IQVIA Stock Up 1.3 %

IQV opened at $212.96 on Wednesday. IQVIA Holdings Inc. has a one year low of $190.20 and a one year high of $261.73. The company has a debt-to-equity ratio of 1.76, a quick ratio of 0.81 and a current ratio of 0.81. The stock has a market capitalization of $38.65 billion, a P/E ratio of 27.95, a price-to-earnings-growth ratio of 2.07 and a beta of 1.51. The business’s 50-day simple moving average is $232.84 and its 200-day simple moving average is $229.54.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.